US › Healthcare

Aclaris Therapeutics Inc (ACRS)

US · Healthcare · Biotechnology

$5.98+8.14%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$2.0M
Revenue YoY
+37.2%
Net profit
$-19.8M
Profit YoY
-31.4%
EPS
$-0.15
EPS estimate
$-0.16
Net margin
-993.2%

EPS came in at -0.15 against a street estimate of -0.16 — a beat of 6.3%.

Key statistics

Market cap
$726.3M
Forward P/E
0.0
P/B
5.06
Book value
$1.03
EPS (TTM)
$-0.56
52-week high
$5.88
52-week low
$1.52
50-day MA
$4.97
200-day MA
$3.74
Beta
0.77

Analyst view

Analysts rate Aclaris Therapeutics Inc a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $10.00.

Shareholding

Insiders
2.28%
Institutions
79.79%

Largest institutional holders

FundStake
BML Capital Management LLC10.20%
Deep Track Capital, LP6.69%
BlackRock Inc5.30%
RA Capital Management, LLC4.87%
Vivo Capital, LLC4.77%
Vanguard Capital Management, LLC3.70%
Frazier Life Sciences Management, L.P.3.53%
Rock Springs Capital Management LP3.20%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Aclaris Therapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.